EUS Guided HVA and PVA for Circulating Tumor DNA in Patients
Endoscopic Ultrasound Guided Hepatic and Portal Vein Aspiration for Circulating Tumor DNA in Patients Suffering From GI Cancers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Shannon Chan, FRCSEd
- Phone Number: 852-35052627
- Email: shannonchan@surgery.cuhk.edu.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- The Chinese University of Hong Kong
-
Contact:
- Shannon Chan, FRCSEd
- Phone Number: 852-35052627
- Email: shannonchan@surgery.cuhk.edu.hk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age >= 18 years old
- Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer
Undergoing treatment with either:
- Surgery
- Neoadjuvant chemotherapy
- Neoadjuvant chemoirradiation
Palliative chemotherapy/ immunotherapy
Exclusion criteria:
- Synchronous cancer of other sites
- Cardia, high lesser curve tumors, oesophagogastric junction tumors
- Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein
- Patients with coagulopathy (international normalized ratio >1.3, partial thromboplastin time greater than twice that of control), platelet count <50,000x103/uL
- Patients unwilling to undergo follow-up assessments
- Patients with liver cirrhosis, portal hypertension and/ or gastric varices
Patient refusal to participate
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: EUS-guided PVA and HVA
Patient will undergo EUS-guided PVA and HVA
|
EUS-guided portal vein and hepatic vein aspiration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variant allelic fraction (expressed in %) of serum ctDNA from HVB, PVB and peripheral blood
Time Frame: 3 months
|
Plasma DNA will be extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen), and the concentration of the circulating tumor DNA will be reported in variant allelic fraction (expressed in %)
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variant allelic fraction (expressed in %) of Genomic and proteomic analysis of ctDNA
Time Frame: 3 months
|
If ctDNA is identified, further genomic and proteomic analysis will be performed.
It will be measured in terms variant allelic fraction (expressed in %)
|
3 months
|
|
Staging of the GI cancer
Time Frame: 3 months
|
The pathological TNM staging of the resected specimen will be recorded.
|
3 months
|
|
Recurrence
Time Frame: 5 years
|
any recurrence of the tumor will be recorded
|
5 years
|
|
Overall survival
Time Frame: 5 years
|
overall survival will be recorded
|
5 years
|
|
Progression-free survival
Time Frame: 5 years
|
progression free survival will be recorded
|
5 years
|
|
Technical success rate of EUS-PVA and HVA
Time Frame: 1 day
|
The technical success rate of the EUS guided procedure will be recorded.
Reasons for failure of the cases will be recorded.
|
1 day
|
|
Adverse events of EUS-PVA and HVA
Time Frame: 30 days
|
the adverse events of the EUS procedure will be recorded
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020.321
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.